CVE-2022-38801

CVE-2022-38801 is a medium-severity vulnerability in Zkteco Biotime with a CVSS 3.x base score of 5.4. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-79.

Key facts

Description

In Zkteco BioTime < 8.5.3 Build:20200816.447, an employee can hijack an administrator session and cookies using blind cross-site scripting.

Frequently asked questions

What is CVE-2022-38801?
In Zkteco BioTime < 8.5.3 Build:20200816.447, an employee can hijack an administrator session and cookies using blind cross-site scripting.
How severe is CVE-2022-38801?
CVE-2022-38801 has a CVSS 3.x base score of 5.4, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and user interaction. Impact on confidentiality is low, integrity low, and availability none.
Is CVE-2022-38801 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (26th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2022-38801?
CVE-2022-38801 affects Zkteco Biotime. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2022-38801?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2022-38801 published?
CVE-2022-38801 was published on 2022-11-30 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Zkteco Biotime

All CVEs affecting Zkteco Biotime →

Other CWE-79 (Cross-site Scripting (XSS)) vulnerabilities

Browse all CWE-79 (Cross-site Scripting (XSS)) vulnerabilities →